サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1542950

造影剤の世界市場：2024年～2031年

Global Contrast Agents Market - 2024-2031

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
造影剤の世界市場：2024年～2031年
出版日: 2024年08月26日
発行: DataM Intelligence
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポート概要

造影剤の世界市場は2023年に62億米ドルに達し、2031年には98億6,000万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは6.1%で成長する見込みです。

造影剤は、医療用画像診断において体内の構造物や体液のコントラストを高めます。造影剤は外部の電磁気や超音波を吸収したり変化させたりするもので、放射線を放出する放射性医薬品とは異なります。造影剤は、画像診断のコントラスト分解能を向上させることにより、病態の特徴を明らかにすることを目的として開発された一群の化学薬剤です。特定の造影剤は、あらゆる構造画像モダリティと考えられるあらゆる投与経路用に開発されてきました。

硫酸バリウム造影剤は何十年もの間使用されており、消化管検査用の経口剤として確立しています。その使用は一般にX線透視検査に限られています。ヨード系造影剤は、X線撮影、透視、血管造影、CT撮影に使用される主要な造影剤です。ヨード系造影剤は、静脈内、経口、尿道、関節内などの投与経路で使用される汎用性の高い薬剤です。

市場力学：

促進要因

放射線・診断センターの増加と増加、放射線・診断分野の進歩

世界の造影剤市場の需要は、複数の要因によって牽引されています。放射線診断センター数の増加と増加は、造影剤市場の主要な牽引要因の一つです。また、様々な診断や放射線治療に対する人々の意識の高まりも市場の拡大につながります。

Healthcare Radiusによると、インドの画像診断市場は今後5年間で12～15％のCAGRを記録すると予想されています。この数字は、5％とされる世界のCAGRよりも大きいです。慢性疾患の有病率の上昇、画像処理技術の採用増加、高齢者人口の増加が成長を押し上げると予想されます。

慢性疾患、心血管系疾患、遺伝子変異、消化器系疾患の増加はすべて業界にプラスの影響を与えると予想されます。ヘルスケア分野への支出の増加や消費者の意識の高まりも、画像診断・放射線検査業界に弾みをつけると思われます。

抑制要因

造影剤の世界市場における主な抑制要因の1つは、造影剤の使用に伴う副作用やアレルギー反応です。診断手技中に、身体に悪影響を及ぼす副作用が観察される人が少なからずいます。NIHが発表した論文によると、非イオン性造影剤に対する即時型反応の発生率は、0.01～0.04％（重度）から3％（軽度）です。非イオン性造影剤はリスクが少ないです。

もう一つの抑制要因は、画像診断の進歩による高コストです。コストが高いため、造影剤の使用は一部の人々に限られています。

市場セグメンテーション

世界の造影剤市場は、タイプ、用途、モダリティ、エンドユーザー、地域によって区分されます。

CTスキャンは造影剤の世界市場シェアの約48.7%を占める。

造影剤はCTスキャンに広く使用されています。コンピュータ断層撮影（CTまたはCATスキャン）は、特殊なX線装置と高度なコンピュータ技術を組み合わせて、身体の水平方向と垂直方向の断面画像（しばしばスライスと呼ばれる）を作成する非侵襲的な画像診断法です。検査部位のこれらの断面画像は、コンピュータのモニター上で検査したり、印刷したりすることができます。

CTスキャンで使用される造影剤の主成分はヨードです。CT造影剤にはイオン性と非イオン性の2種類があります。現在、CTスキャンでは非イオン性造影剤が最も広く使用されています。ジェファーソン放射線学によると、造影剤を使用したCTスキャンは、骨、血管、臓器などの内部構造を可視化するために広く使用されています。特に腫瘍、血管疾患、内出血の発見に有用です。

例えば、Fresenius Kabiは2022年7月、米国で造影剤のジェネリック医薬品を導入すると発表しました。Iodixanol Injection, USPは、米国FDAが承認した初の等浸透圧二量体ヨード造影剤のジェネリック医薬品であり、コンピュータ断層撮影（CT）スキャンなどのX線ベースの画像診断で使用されます。

地域別市場分析

北米が造影剤の世界市場シェアの約49.2%を占める

予測期間中、北米地域が最大の市場シェアを占めると予想されます。同地域では、放射線科や診断センターの増加、人々の意識の高まりが市場の推進力となっています。

北米地域には大手企業が進出しているため、診断や放射線治療が進んでいます。長期的な病気や複雑な合併症の発生率の上昇、民間および当局の費用の増加などの要因が、米国北部の市場拡大のガソリンになると予想されます。

例えば、2024年1月、ケース・ウェスタン・リザーブ大学の研究者は、化学的画像造影剤に代わる人工知能ベースの研究開発を開始しました。CWRUは最近、全米科学財団から4年間で112万5,000ドルの助成金を獲得しました。彼らは、CT、MR、X線検査の際に、ガドリニウムなどの物質を注入することなく画像を強化する新たなアプローチを生み出すために全力を尽くしています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 放射線診断センターの増加
      • 診断分野における進歩
      • 世界人口における慢性疾患の増加

第5章 抑制要因

  • 造影剤の高コスト
  • 造影剤使用に伴う副作用

第6章 機会

第7章 影響分析

第8章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • PESTEL分析
  • 特許分析
  • SWOT分析

第9章 タイプ別

  • バリウム系造影剤
  • ヨード系造影剤
  • ガドリニウム系造影剤
  • マイクロバブル系造影剤
  • その他

第10章 用途別

  • 腫瘍学
  • 循環器
  • 神経内科
  • その他

第11章 モダリティ別

  • X線/CT
  • MRI
  • 超音波
  • その他

第12章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 診断センター
  • その他

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第14章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第15章 企業プロファイル

  • Bayer AG
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • GE Health Care
  • Bracco diagnostics Inc.,
  • Lantheus Medical Imaging
  • Nano Therapeutics Pvt Ltd.
  • Unijules Life Sciences Ltd.,
  • Guerbet SA
  • Trivitron Healthcare
  • Spago Nanomedical AB
  • Taejoon Pharma

第16章 付録

目次
Product Code: MD99

Report Overview

The Global Contrast Agents Market reached US$ 6.2 billion in 2023 and is expected to reach US$ 9.86 billion by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

A contrast agent (or contrast medium) increases the contrast of structures or fluids within the body in medical imaging. Contrast agents absorb or alter external electromagnetism or ultrasound, which differs from radiopharmaceuticals, which emit radiation. Contrast agents are a group of chemical agents developed to aid in the characterization of pathology by improving the contrast resolution of an imaging modality. Specific contrast agents have been developed for every structural imaging modality and every conceivable route of administration.

Barium sulfate contrast media have been used for many decades, and are well-established as oral agents for the examination of the GI tract. Their use is generally restricted to radiographic and fluoroscopic examinations. Iodinated contrast media are the mainstay contrast agents for use in radiographic, fluoroscopic, angiographic, and CT imaging. They are a versatile group of agents used for intravenous, oral, and other routes of administration, such as urethral and intra-articular.

Market Dynamics: Drivers

The rise and increase in the number of radiology and diagnostic centers and advancements in the field of radiology and diagnostics

The demand for the global contrast agents market is driven by multiple factors. The rise and increase in the number of radiology and diagnostic centers is one of the major driving factors in the contrast agents market. The increased awareness among people about various diagnostic and radiology procedures also leads to an increase in the market.

According to the healthcare radius, the Indian diagnostic imaging market is expected to register a compounded annual growth rate (CAGR) of 12-15 percent over the next five years. This number is greater than the global CAGR rate which is pegged at five percent. The rise in prevalence of chronic diseases, increased adoption of technologies in imaging, and a growing elderly/geriatric population are expected to boost the growth.

The increasing incidences of chronic diseases, cardiovascular disorders, genetic mutations, and GI disorders are all expected to impact the industry positively. Increased expenditure on the healthcare sector and greater consumer awareness will also give an impetus to the imaging and radiology industry.

Restraints

One of the major restraints in the global contrast agents market is the side effects and allergic reactions that are associated with the usage of contrast agents. In a few people during the diagnostic procedures, side effects are observed which causes a negative impact on the body. According to an article published by NIH, the incidence of immediate reactions to non-ionic contrast media ranges from, 0.01-0.04%(severe) to 3%(mild). Non-ionic agents are associated with less risk.

Another restraint is the high cost due to advancements in imaging procedures. The high cost limits the usage of contrast agents to certain segments of people.

Market Segment Analysis

The global contrast agents market is segmented based on type, application, modality, end-user, and region.

The segment CT scan accounted for approximately 48.7% of the global contrast agents market share

The contrast agents are widely used in the procedure of CT scans. Computed tomography scan (CT or CAT scan) is a non-invasive diagnostic imaging procedure that uses a combination of special X-ray equipment and sophisticated computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body. These cross-sectional images of the area being studied can then be examined on a computer monitor or printed.

The main component of the contrast material used in the CT scan is iodine. The CT contrast agents are of two types: ionic and non-ionic. At present, in CT scans the non-ionic contrast agents are most widely used. According to Jefferson radiology, CT scans with contrast agents are widely used to visualize internal structures such as bones, blood vessels, and organs. They are particularly useful in detecting tumors, vascular diseases, and internal bleeding.

For instance, in July 2022, Fresenius Kabi announced that it would introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of Iodixanol Injection, USP, a product the U.S. Food and Drug Administration (FDA) lists as being in shortage nationwide. Iodixanol Injection, USP is the first U.S. FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic x-ray-based imaging such as computed tomography (CT) scans.

Market Geographical Analysis

North America accounted for approximately 49.2% of the global contrast agents market share

North America region is expected to hold the largest market share over the forecast period. The increase in the number of radiology and diagnostic centers, and growing awareness among people, in this region, help to propel the market.

Due to the presence of major players in the region of North America, it has advancements in diagnostic and radiology procedures. Factors including the rising incidence of long-term sicknesses and complicated comorbidities and increasing private and authority fees are expected to gasoline market increase in the North U.S.

For instance, in January 2024, Scientists with Case Western Reserve University started researching and working on the development of an artificial intelligence-based alternative to chemical imaging contrast agents. CWRU recently scored a four-year, $1.125 million grant from the National Science Foundation to help fuel its work. They are working their best to create a new approach during CT, MR, and X-ray exams, enhancing images without injecting substances such as gadolinium.

Market Segmentation

By Type

  • Barium-based contrast media
  • Iodinated contrast media
  • Gadolinium-based contrast medium
  • Microbubble-based contrast media

By Application

  • Oncology
  • Cardiology
  • Neurology
  • Others

By Modality

  • X-Ray / CT
  • MRI
  • Ultrasound
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the global contrast agents market include Bayer AG, GE Health care, Bracco Diagnostics Inc., Lantheus Medical Imaging, Inc., Nano Therapeutics Pvt Ltd., Unijules Life Sciences Ltd., Guerbet SA, Trivitron Healthcare, Spago Nanomedical AB, Taejoon Pharma among others.

Key Developments

  • In September 2022, Bracco Diagnostics Inc., the United States (U.S.) subsidiary of Bracco Imaging S.p.A., an innovative world leader in diagnostic imaging, announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA), which shows the highest relaxivity compared to all the other GBCAs available today in the United States.
  • In February 2023, Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced the commercial launch and dosing of the first patient with Elucirem(TM) (gadopiclenol) injection following FDA approval in 2022. This next-generation GBCA from Guerbet, a highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.

Why Purchase the Report?

  • To visualize the global contrast agents market segmentation based on type, application, modality, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global contrast agents market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global contrast agents market report would provide approximately 78 tables, figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Modality
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing the number of radiology and diagnostic centers
      • 4.1.1.2. Advancements in the field of diagnostics
      • 4.1.1.3. Increase in the number of chronic diseases in the global population

5. Restraints

  • 5.1. High cost of the contrast agents
  • 5.2. Side effects associated with usage of contrast agents

6. Opportunity

7. Impact Analysis

8. Industry Analysis

  • 8.1. Porter's Five Force Analysis
  • 8.2. Supply Chain Analysis
  • 8.3. Pricing Analysis
  • 8.4. Regulatory Analysis
  • 8.5. Unmet Needs
  • 8.6. PESTEL Analysis
  • 8.7. Patent Analysis
  • 8.8. SWOT Analysis

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Barium based contrast media*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Iodinated contrast media
  • 9.4. Gadolinium-based contrast media
  • 9.5. Microbubble-based contrast media
  • 9.6. Others

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Oncology*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Cardiology
  • 10.4. Neurology
  • 10.5. Others

11. By Modality

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.1.2. Market Attractiveness Index, By Modality
  • 11.2. X-Ray / CT*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. MRI
  • 11.4. Ultrasound
  • 11.5. Others

12. By End-User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.1.2. Market Attractiveness Index, By End-User
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Specialty Clinics
  • 12.4. Diagnostic Centers
  • 12.5. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. UK
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. South Korea
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Positioning/Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Bayer AG*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. GE Health Care
  • 15.3. Bracco diagnostics Inc.,
  • 15.4. Lantheus Medical Imaging
  • 15.5. Nano Therapeutics Pvt Ltd.
  • 15.6. Unijules Life Sciences Ltd.,
  • 15.7. Guerbet SA
  • 15.8. Trivitron Healthcare
  • 15.9. Spago Nanomedical AB
  • 15.10. Taejoon Pharma (*LIST NOT EXHAUSTIVE)

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us